{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:37:16Z","timestamp":1794645436494,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP15ck0106144"],"award-info":[{"award-number":["JP15ck0106144"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP18ck0106416"],"award-info":[{"award-number":["JP18ck0106416"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20lm0203140"],"award-info":[{"award-number":["JP20lm0203140"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This investigator-initiated, phase 2, single-arm trial primarily assessed the efficacy of G47\u2206, a triple-mutated, third-generation oncolytic herpes simplex virus type 1, in 19 adult patients with residual or recurrent, supratentorial glioblastoma after radiation therapy and temozolomide (UMIN-CTR Clinical Trial Registry UMIN000015995). G47\u0394 was administered intratumorally and repeatedly for up to six doses. The primary endpoint of 1-yr survival rate after G47\u2206 initiation was 84.2% (95% confidence interval, 60.4\u201396.6; 16 of 19). The prespecified endpoint was met and the trial was terminated early. Regarding secondary endpoints, the median overall survival was 20.2 (16.8\u201323.6)\u2009months after G47\u2206 initiation and 28.8 (20.1\u201337.5)\u2009months from the initial surgery. The most common G47\u2206-related adverse event was fever (17 of 19) followed by vomiting, nausea, lymphocytopenia and leukopenia. On magnetic resonance imaging, enlargement of and contrast-enhancement clearing within the target lesion repeatedly occurred after each G47\u2206 administration, which was characteristic to this therapy. Thus, the best overall response in 2\u2009yr was partial response in one patient and stable disease in 18 patients. Biopsies revealed increasing numbers of tumor-infiltrating CD4\n                    <jats:sup>+<\/jats:sup>\n                    \/CD8\n                    <jats:sup>+<\/jats:sup>\n                    lymphocytes and persistent low numbers of Foxp3\n                    <jats:sup>+<\/jats:sup>\n                    cells. This study showed a survival benefit and good safety profile, which led to the approval of G47\u2206 as the first oncolytic virus product in Japan.\n                  <\/jats:p>","DOI":"10.1038\/s41591-022-01897-x","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T12:04:22Z","timestamp":1658405062000},"page":"1630-1639","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":548,"title":["Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: a phase 2 trial"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0523-8010","authenticated-orcid":false,"given":"Tomoki","family":"Todo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2609-1962","authenticated-orcid":false,"given":"Yasushi","family":"Ino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3261-8828","authenticated-orcid":false,"given":"Hiroshi","family":"Ohtsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Shibahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3600-1948","authenticated-orcid":false,"given":"Minoru","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,21]]},"reference":[{"key":"1897_CR1","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp, R. et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318, 2306\u20132316 (2017).","journal-title":"JAMA"},{"key":"1897_CR2","doi-asserted-by":"publisher","first-page":"6396","DOI":"10.1073\/pnas.101136398","volume":"98","author":"T Todo","year":"2001","unstructured":"Todo, T., Martuza, R. L., Rabkin, S. D. & Johnson, P. A. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc. Natl Acad. Sci. USA 98, 6396\u20136401 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1897_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-018-0281-9","volume":"19","author":"W Ma","year":"2018","unstructured":"Ma, W., He, H. & Wang, H. Oncolytic herpes simplex virus and immunotherapy. BMC Immunol. 19, 40 (2018).","journal-title":"BMC Immunol."},{"key":"1897_CR4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1358\/dof.2010.35.3.1470166","volume":"35","author":"J Carson","year":"2010","unstructured":"Carson, J., Haddad, D., Bressman, M. & Fong, Y. Oncolytic herpes simplex virus 1 (HSV-1) vectors: increasing treatment efficacy and range through strategic virus design. Drugs Future 35, 183\u2013195 (2010).","journal-title":"Drugs Future"},{"key":"1897_CR5","unstructured":"Todo, T., Ino, Y., Ohtsu, H., Shibahara, J. & Tanaka, M. A phase I\/II study of triple-mutated oncolytic herpes virus G47\u2206 in patients with progressive glioblastoma. Nature Commun. (in the press)."},{"key":"1897_CR6","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/S0140-6736(11)60828-3","volume":"378","author":"N Ikegami","year":"2011","unstructured":"Ikegami, N. et al. Japanese universal health coverage: evolution, achievements, and challenges. Lancet 378, 1106\u20131115 (2011).","journal-title":"Lancet"},{"key":"1897_CR7","doi-asserted-by":"publisher","first-page":"4193","DOI":"10.1002\/cncr.27372","volume":"118","author":"T Koga","year":"2012","unstructured":"Koga, T. et al. Extended field stereotactic radiosurgery for recurrent glioblastoma. Cancer 118, 4193\u20134200 (2012).","journal-title":"Cancer"},{"key":"1897_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1215\/15228517-2006-025","volume":"9","author":"KV Ballman","year":"2007","unstructured":"Ballman, K. V. et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol. 9, 29\u201338 (2007).","journal-title":"Neuro Oncol."},{"key":"1897_CR9","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s00415-009-5006-9","volume":"256","author":"A Wick","year":"2009","unstructured":"Wick, A. et al. Rechallenge with temozolomide in patients with recurrent gliomas. J. Neurol. 256, 734\u2013741 (2009).","journal-title":"J. Neurol."},{"key":"1897_CR10","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman, H. S. et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27, 4733\u20134740 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1897_CR11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.4103\/2278-330X.175953","volume":"4","author":"S Roy","year":"2015","unstructured":"Roy, S., Lahiri, D., Maji, T. & Biswas, J. Recurrent glioblastoma: where we stand. South Asian J. Cancer 4, 163\u2013173 (2015).","journal-title":"South Asian J. Cancer"},{"key":"1897_CR12","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3390\/cancers12030586","volume":"12","author":"CG Brahm","year":"2020","unstructured":"Brahm, C. G. et al. The current status of immune checkpoint inhibitors in neuro-oncology: a systematic review. Cancers (Basel) 12, 586 (2020).","journal-title":"Cancers (Basel)"},{"key":"1897_CR13","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","volume":"48","author":"R Stupp","year":"2012","unstructured":"Stupp, R. et al. NovoTTF-100A versus physician\u2019s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur. J. Cancer 48, 2192\u20132202 (2012).","journal-title":"Eur. J. Cancer"},{"key":"1897_CR14","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11060-016-2157-2","volume":"129","author":"JJ Mandel","year":"2016","unstructured":"Mandel, J. J. et al. Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma. J. Neurooncol. 129, 147\u2013154 (2016).","journal-title":"J. Neurooncol."},{"key":"1897_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/neuonc\/5.2.79","volume":"5","author":"M Westphal","year":"2003","unstructured":"Westphal, M. et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 5, 79\u201388 (2003).","journal-title":"Neuro Oncol."},{"key":"1897_CR16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00701-005-0707-z","volume":"148","author":"M Westphal","year":"2006","unstructured":"Westphal, M., Ram, Z., Riddle, V., Hilt, D. & Bortey, E. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir. (Wien) 148, 269\u2013275; discussion 275 (2006).","journal-title":"Acta Neurochir. (Wien)"},{"key":"1897_CR17","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s00701-012-1413-2","volume":"154","author":"P De Bonis","year":"2012","unstructured":"De Bonis, P. et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma. Acta Neurochir. (Wien) 154, 1371\u20131378 (2012).","journal-title":"Acta Neurochir. (Wien)"},{"key":"1897_CR18","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 23, 1231\u20131251 (2021).","journal-title":"Neuro Oncol."},{"key":"1897_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14791\/btrt.2017.5.1.1","volume":"5","author":"Y Li","year":"2017","unstructured":"Li, Y., Ali, S., Clarke, J. & Cha, S. Bevacizumab in recurrent glioma: patterns of treatment failure and implications. Brain Tumor Res. Treat. 5, 1\u20139 (2017).","journal-title":"Brain Tumor Res. Treat."},{"key":"1897_CR20","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/sj.gt.3301003","volume":"6","author":"A Chahlavi","year":"1999","unstructured":"Chahlavi, A., Rabkin, S. D., Todo, T., Sundaresan, P. & Martuza, R. L. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther. 6, 1751\u20131758 (1999).","journal-title":"Gene Ther."},{"key":"1897_CR21","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1897_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2174\/157488606776930535","volume":"1","author":"A Dario","year":"2006","unstructured":"Dario, A. & Tomei, G. The safety of the temozolomide in patients with malignant glioma. Curr. Drug Saf. 1, 205\u2013222 (2006).","journal-title":"Curr. Drug Saf."},{"key":"1897_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","volume":"335","author":"AE Coutinho","year":"2011","unstructured":"Coutinho, A. E. & Chapman, K. E. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol. Cell. Endocrinol. 335, 2\u201313 (2011).","journal-title":"Mol. Cell. Endocrinol."},{"key":"1897_CR24","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJMoa1716435","volume":"379","author":"A Desjardins","year":"2018","unstructured":"Desjardins, A. et al. Recurrent glioblastoma treated with recombinant poliovirus. N. Engl. J. Med. 379, 150\u2013161 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1897_CR25","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/sj.gt.3301205","volume":"7","author":"JM Markert","year":"2000","unstructured":"Markert, J. M. et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 7, 867\u2013874 (2000).","journal-title":"Gene Ther."},{"key":"1897_CR26","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/mt.2008.228","volume":"17","author":"JM Markert","year":"2009","unstructured":"Markert, J. M. et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre- and post-tumor resection for recurrent GBM. Mol. Ther. 17, 199\u2013207 (2009).","journal-title":"Mol. Ther."},{"key":"1897_CR27","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/mt.2014.22","volume":"22","author":"JM Markert","year":"2014","unstructured":"Markert, J. M. et al. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol. Ther. 22, 1048\u20131055 (2014).","journal-title":"Mol. Ther."},{"key":"1897_CR28","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1089\/10430349950016591","volume":"10","author":"T Todo","year":"1999","unstructured":"Todo, T., Rabkin, S. D., Chahlavi, A. & Martuza, R. L. Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy. Hum. Gene Ther. 10, 2869\u20132878 (1999).","journal-title":"Hum. Gene Ther."},{"key":"1897_CR29","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.immuni.2018.12.016","volume":"50","author":"F Van Gool","year":"2019","unstructured":"Van Gool, F. et al. A mutation in the transcription factor Foxp3 drives T helper 2 effector function in regulatory T cells. Immunity 50, 362\u2013377.e366 (2019).","journal-title":"Immunity"},{"key":"1897_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","volume":"7","author":"RHI Andtbacka","year":"2019","unstructured":"Andtbacka, R. H. I. et al. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III\u2013IV melanoma. J. ImmunoTher. Cancer 7, 145 (2019).","journal-title":"J. ImmunoTher. Cancer"},{"key":"1897_CR31","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-06-3145","volume":"67","author":"M Aghi","year":"2007","unstructured":"Aghi, M., Rabkin, S. D. & Martuza, R. L. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res. 67, 440\u2013444 (2007).","journal-title":"Cancer Res."},{"key":"1897_CR32","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.annonc.2021.03.197","volume":"32","author":"AB Carpenter","year":"2021","unstructured":"Carpenter, A. B., Carpenter, A. M., Aiken, R. & Hanft, S. Oncolytic virus in gliomas: a review of human clinical investigations. Ann. Oncol. 32, 968\u2013982 (2021).","journal-title":"Ann. Oncol."},{"key":"1897_CR33","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","volume":"36","author":"FF Lang","year":"2018","unstructured":"Lang, F. F. et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J. Clin. Oncol. 36, 1419\u20131427 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1897_CR34","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2024947","volume":"384","author":"GK Friedman","year":"2021","unstructured":"Friedman, G. K. et al. Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas. N. Engl. J. Med. 384, 1613\u20131622 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1897_CR35","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/cas.13027","volume":"107","author":"H Fukuhara","year":"2016","unstructured":"Fukuhara, H., Ino, Y. & Todo, T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 107, 1373\u20131379 (2016).","journal-title":"Cancer Sci."},{"key":"1897_CR36","doi-asserted-by":"publisher","first-page":"7886","DOI":"10.1158\/1078-0432.CCR-05-1090","volume":"11","author":"H Fukuhara","year":"2005","unstructured":"Fukuhara, H., Martuza, R. L., Rabkin, S. D., Ito, Y. & Todo, T. Oncolytic herpes simplex virus vector G47\u0394 in combination with androgen ablation for the treatment of human prostate adenocarcinoma. Clin. Cancer Res. 11, 7886\u20137890 (2005).","journal-title":"Clin. Cancer Res."},{"key":"1897_CR37","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.omto.2020.03.022","volume":"17","author":"K Sugawara","year":"2020","unstructured":"Sugawara, K. et al. Efficacy of a third-generation oncolytic herpes virus G47\u0394 in advanced stage models of human gastric cancer. Mol. Ther. Oncolytics 17, 205\u2013215 (2020).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1897_CR38","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.omto.2020.08.010","volume":"18","author":"T Yamada","year":"2020","unstructured":"Yamada, T., Tateishi, R., Iwai, M., Koike, K. & Todo, T. Neoadjuvant use of oncolytic herpes virus G47\u0394 enhances the antitumor efficacy of radiofrequency ablation. Mol. Ther. Oncolytics 18, 535\u2013545 (2020).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1897_CR39","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/sj.gt.3302445","volume":"12","author":"R Liu","year":"2005","unstructured":"Liu, R., Martuza, R. L. & Rabkin, S. D. Intracarotid delivery of oncolytic HSV vector G47\u2206 to metastatic breast cancer in the brain. Gene Ther. 12, 647\u2013654 (2005).","journal-title":"Gene Ther."},{"key":"1897_CR40","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.omto.2021.06.008","volume":"22","author":"T Uchihashi","year":"2021","unstructured":"Uchihashi, T. et al. Oncolytic herpes virus G47\u0394 injected into tongue cancer swiftly traffics in lymphatics and suppresses metastasis. Mol. Ther. Oncolytics 22, 388\u2013398 (2021).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1897_CR41","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.omto.2021.10.012","volume":"23","author":"S Yajima","year":"2021","unstructured":"Yajima, S. et al. Efficacy and safety of a third-generation oncolytic herpes virus G47\u2206 in models of human esophageal carcinoma. Mol. Ther. Oncolytics 23, 402\u2013411 (2021).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1897_CR42","first-page":"3009","volume":"61","author":"A Wu","year":"2001","unstructured":"Wu, A. et al. Biological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation. Cancer Res. 61, 3009\u20133015 (2001).","journal-title":"Cancer Res."},{"key":"1897_CR43","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.ymthe.2020.09.041","volume":"29","author":"R Ishino","year":"2021","unstructured":"Ishino, R. et al. Oncolytic virus therapy with HSV-1 for hematological malignancies. Mol. Ther. 29, 762\u2013774 (2021).","journal-title":"Mol. Ther."},{"key":"1897_CR44","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/bjh.17173","volume":"192","author":"M Oku","year":"2021","unstructured":"Oku, M. et al. Oncolytic herpes simplex virus type 1 (HSV-1) in combination with lenalidomide for plasma cell neoplasms. Br. J. Haematol. 192, 343\u2013353 (2021).","journal-title":"Br. J. Haematol."},{"key":"1897_CR45","doi-asserted-by":"publisher","first-page":"B116","DOI":"10.1158\/2326-6066.IMM2016-B116","volume":"4","author":"D Saha","year":"2016","unstructured":"Saha, D., Martuza, R. & Rabkin, S. Abstract B116: Immunovirotherapy in combination with immune checkpoint inhibitors for treating glioblastoma. Cancer Immunol. Res. 4, B116\u2013B116 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"1897_CR46","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.omto.2021.05.004","volume":"22","author":"K Sugawara","year":"2021","unstructured":"Sugawara, K. et al. Oncolytic herpes virus G47\u0394 works synergistically with CTLA-4 inhibition through dynamic intratumoral immune modulation. Mol. Ther. Oncolytics 22, 129\u2013142 (2021).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1897_CR47","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412\u20137420 (2009).","journal-title":"Clin. Cancer Res."}],"updated-by":[{"DOI":"10.1038\/s41591-025-03619-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01897-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01897-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01897-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T03:32:02Z","timestamp":1742355122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01897-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,21]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1897"],"URL":"https:\/\/doi.org\/10.1038\/s41591-022-01897-x","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,21]]},"assertion":[{"value":"16 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-025-03619-5","URL":"https:\/\/doi.org\/10.1038\/s41591-025-03619-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.T. owns the patent right for G47\u2206 in Japan. All other authors have no conflict of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}